期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EB病毒相关淋巴瘤研究进展

Research Progress of Epstein Barr Virus Associated Lymphoma
下载PDF
导出
摘要 Eb病毒(Epstein-Barr virus, EBV)属疱疹病毒群,为双链DNA病毒,超过90%的成年人为EBV健康携带者,尽管在绝大多数携带者中无害,EBV却以不同比例存在于多种免疫力看似正常的不同类型淋巴瘤及上皮细胞肿瘤患者的癌细胞中,包括伯基特淋巴瘤、霍奇金淋巴瘤、弥漫大B细胞淋巴瘤等。EBV相关淋巴瘤的发病机理与病毒基因表达及细胞基因表达间存在着复杂的关系,现就几种常见淋巴瘤中EBV的作用机制及相关研究进展进行综述。 Epstein Barr virus (EBV) is a new type of virus. EBV belongs to herpesvirus group, which is double stranded DNA virus. More than 90% of adults are healthy EBV carriers. Although it is harmless in most of the carriers, EBV exists in different proportions in cancer cells of different types of lymphoma and epithelial cell tumor patients with normal immunity, including Burkitt’s lymphoma, Hodgkin’s lymphoma, diffuse large B-cell lymphoma, etc. There is a complex relationship between the pathogenesis of EBV associated lymphoma and the gene expression of virus and cell. This article reviews the mechanism of EBV in several common lymphomas and the related research progress.
作者 郝园园 林森森
机构地区 中国药科大学
出处 《世界肿瘤研究》 2021年第2期38-47,共10页 World Journal of Cancer Research
关键词 EB病毒 伯基特淋巴瘤 霍奇金淋巴瘤 弥漫大B细胞淋巴瘤
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献25

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献244

世界肿瘤研究
2021年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部